Solving the production problem with ENBREL?
From IMMUNEX 8-K/A SEC filing on 08/30/2000:
Re: Memorandum of Understanding Regarding Greenwich Holding's West Greenwich, RI Biopharmaceutical Facility
Greenwich Holdings Inc. ("Greenwich"), a wholly-owned subsidiary of American
Home Products Corporation ("AHPC"), entered into a definitive Asset Purchase
Agreement (the "Purchase Agreement") with Glaxo Wellcome Biopharmaceuticals Inc.
("GWBI"), a wholly-owned subsidiary of Glaxo Wellcome Inc. ("GW") dated as of
August 23, 1999, to purchase all the real property and biological manufacturing
facility located at 40 Technology Way, West Greenwich, Rhode Island, also known
as the "Wel Gen" facility (the "Facility") from GWBI. On September 24, 1999,
Greenwich consummated the purchase of the Facility pursuant to the terms of the
Purchase Agreement.
Greenwich/AHPC and Immunex Corporation, together with its Affiliates (as defined
below) ("Immunex"), by combining the strengths and competencies of each party,
intend to retrofit "Suites A and D" of the Facility (hereinafter referred to
solely as "Suite A") by mid-2001 to accommodate the commercial manufacture of
ENBREL(R) (etanercept), to perform the initial validation runs for ENBREL and to
commence commercial production of ENBREL. Greenwich/AHPC and Immunex are
exploring the potential of installing equipment and capital improvements in
"Suite B" of the Facility ("Phase A-3") to accommodate future commercial
manufacturing needs for ENBREL. Immunex is exploring the potential of building
additional biotechnology manufacturing capacity on vacant land located at the
Facility outside the footprint of the existing Suites ("Phase B") in a manner
which will not impact the most aggressive accelerated schedule for the retrofit
of Suites A and B (i.e., Phase A-3) of the Facility.
AHPC intends to build a biopharmaceutical manufacturing facility at an affiliate
site of AHPC located in Ireland ("BIOS") for the eventual manufacture of ENBREL,
together with other biotechnology products, and it is anticipated that such site
would be completed in approximately 2004.
Greenwich/AHPC and Immunex have agreed to enter into a Definitive Agreement (as
defined below) regarding the purchase and sale of all of the outstanding capital
stock of Greenwich (the "Greenwich Shares") to Immunex, pursuant to the terms
set forth herein and to be included in the Definitive Agreement. This memorandum
of understanding ("MOU") sets forth the mutual commitments of Greenwich/AHPC and
Immunex with regard to such purchase and sale of the Greenwich Shares, and with
regard to the terms and conditions that will govern the parties' management of
the Facility during the retrofit of Suites A and B (i.e., Phase A-3) of the
Facility. ...
|
